Value, Affordability, and Decision Making

The Virtual ISPOR Europe 2020 will be commencing next week. A number of OHE researchers will be in attendance to present their research.

With the theme Improving Health: Establishing Incentives and Sharing Value, Virtual ISPOR Europe 2020 will question the fundamental conventions around value, risk, rewards, and the role of public and private sectors.

As the world is figuring out how to deal with COVID-19, it is worth taking stock of the broader value that existing vaccines bring to societies suffering from this pandemic. We illustrate this broader value by considering how existing vaccines can help protect people from other respiratory conditions or from COVID-19 co-infections and relieve overburdened healthcare systems.

In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides patients with fair access to a drug with a fair, value-based price. But how do we define fair access? This paper from ICER and OHE authors develops a fair access framework, proposing Ethical Goals for Access and Fair Design Criteria for cost sharing and prior authorization protocols.

Pearson, S., Lowe, M., Towse, A., K., Segel, C. and Henshall, C.

Research Paper
September 2020

In the focus on US drug prices, ICER has contributed thinking on determining when price aligns with patient benefits. Less debated is whether insurance coverage provides patients with fair access to a drug with a fair, value-based, price. But how do we define fair access? This paper from ICER and OHE authors develops a fair access framework, proposing Ethical Goals for Access and Fair Design Criteria for cost sharing and prior authorization protocols.

Bell, E., Neri, M., Steuten, L.

Research Paper
September 2020

OHE is undertaking a research programme called the Broad Assessment of Value in Vaccines Engagement (BRAVE). The overarching aim of the BRAVE initiative is to increase recognition of the broader value elements of vaccines and consistency of their assessment within HTA and wider decision-making processes in various countries, including Belgium, Canada, France, Germany, Italy, Japan, Sweden, the UK and the US.  

The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of not considering productivity costs in the evaluation of vaccination programmes in the UK.

Rodes Sanchez, M., Henderson, N. and Steuten, L. 

Consulting Report
August 2020

Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin, face significant methodological and policy hurdles related to evidence development and acceptance, value assessment and reimbursement pathways, and diagnostic infrastructure availability.

Barros, P.

Seminar Briefing
August 2020

The issue of rising prescription drug prices is a concern in every country. Dozens of policy initiatives and hundreds of research projects over last the fifty years have attempted to find solutions to pricing that provide an appropriate balance between the cost to health care systems and incentives for R&D. To name but a few, these include reference pricing, managed entry agreements, price-volume agreements, rebates, and risk sharing. The ultimate solution, however, remains elusive.

 

In a recently published OHE Consulting Report, we report the long-term return on investment (ROI) per £1 spent on various vaccination programmes from the perspective of the UK government. In this blog, we discuss how discounting affects the estimated long-term value of vaccination and, thus, decision-makers’ investment decisions.

OHE publishes a report quantifying the level of patient access associated with NICE ‘optimised’ recommendations.

Pages

Subscribe to RSS - Value, Affordability, and Decision Making